Ionizing radiation inhibits chemotherapy-induced apoptosis in cultured glioma cells: implications for combined modality therapy.
Surgical resection followed by radiation therapy is the mainstay of treatment for glioblastoma multiforme (GBM), the most aggressive of the malignant gliomas. The poor clinical response of GBM and the intrinsic radiation resistance of this tumor type have prompted clinical investigations seeking to define the role of chemotherapy in the treatment of GBM. In this study, we examined the cytotoxic response of GBM-derived cell lines to treatment with both radiation and chemotherapy. We observed that the sensitivity of glioma cells to cisplatin- and FAS-induced apoptosis was diminished by prior treatment with ionizing radiation. Radiation conferred resistance to cisplatin and FAS cytotoxicity in a dose- and time-dependent manner. Radiation diminished the cisplatin-induced cytotoxicity of malignant glioma cells but failed to alter the cisplatin susceptibility of normal primary human astrocytes. Given the role of p53 in the response of cells to irradiation, we evaluated whether p53 function affects the observed radiation-induced resistance to cisplatin. By examining isogenic cell lines differing only in p53 function, we demonstrated that radiation conferred resistance to cisplatin independently of p53. Current clinical strategies in the treatment of astrocytic tumors, which include combined modality therapy, have been empirically derived from limited clinical experience. Further understanding of the molecular determinants of apoptosis associated with combined modality therapy may guide the design of more efficacious multimodality protocols.
Yount
G L
GL
Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, 94143-0226, USA.
Haas-Kogan
D A
DA
Levine
K S
KS
Aldape
K D
KD
Israel
M A
MA
D017209:Apoptosis / Q000187:drug effects / Q000528:radiation effects*; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016193:G1 Phase; D005909:Glioblastoma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D014407:Tumor Cells, Cultured; D019014:fas Receptor / Q000502:physiology
D019014:fas Receptor; D002945:Cisplatin